Physician profile
James D Knecht
NPI 1023013752
$1,829.03
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $701 · 2021: $695.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $214.17 | 2019-2021 | |
| Novo Nordisk INC | $159.64 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.66 | 2019-2021 | |
| Pfizer INC. | $142.91 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $142.79 | 2021 | |
| Eisai INC. | $135.59 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.33 | 2019-2021 | |
| Genzyme Corporation | $110.00 | 2019 | |
| Lilly USA, LLC | $101.14 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.03 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $94.50 | 2020-2021 | |
| Allergan, INC. | $83.74 | 2019-2020 | |
| Amarin Pharma, INC. | $77.33 | 2019-2021 | |
| Amgen INC. | $77.03 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $54.69 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $31.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.87 | 2021 | |
| Merck Sharp & Dohme LLC | $12.79 | 2021 | |
| Astellas Pharma US INC | $12.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Knecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.